ALNY

Alnylam Pharmaceuticals, Inc. Press Releases

$57.85
*  
0.68
1.16%
Get ALNY Alerts
*Delayed - data as of Jul. 10, 2014  -  Find a broker to begin trading ALNY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Alnylam to Host “RNAi Roundtable” Webcast Series
7/7/2014 8:00:00 AM - Business Wire

Alnylam Elects Amy Schulman to its Board of Directors
7/2/2014 8:00:00 AM - Business Wire

Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
6/30/2014 8:00:00 AM - Business Wire

Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease
6/19/2014 8:58:00 AM - Business Wire

Alnylam to Webcast Presentation at 9th Annual JMP Securities Healthcare Conference
6/17/2014 4:00:00 PM - Business Wire

Scanning Biotech Equities -- Research on ACADIA Pharma, Acorda Therapeutics, Alnylam Pharma, and BioCryst Pharma
6/13/2014 8:20:00 AM - PR Newswire

Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
6/12/2014 8:00:00 AM - Business Wire

Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
6/9/2014 8:00:00 AM - Business Wire

Alnylam to Webcast Presentation at Goldman Sachs 35th Annual Global Healthcare Conference
6/4/2014 4:00:00 PM - Business Wire

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to Ring The NASDAQ Stock Market Opening Bell
5/29/2014 10:00:00 AM - GlobeNewswire

Alnylam and Collaborators Publish Pre-Clinical Results with ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias, in the Proceedings of the National Academy of Sciences
5/21/2014 8:00:00 AM - Business Wire

Biotech Stocks Technical Data -- Research on Alnylam Pharma, Regeneron Pharma, Cel-Sci, and Synta Pharma
5/13/2014 10:15:00 AM - PR Newswire

Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
5/13/2014 8:00:00 AM - Business Wire

Equities Updates on Top Gainers -- Research on athenahealth, Global Eagle Entertainment, TherapeuticsMD, and Alnylam Pharma
5/12/2014 11:30:00 AM - PR Newswire

Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees
5/12/2014 8:00:00 AM - Business Wire

Alnylam Presents Key Scientific Data on Enhanced Stabilization Chemistry (ESC)-GalNAc-Conjugate Technology
5/11/2014 4:00:00 PM - Business Wire

Alnylam Pharmaceuticals Reports First Quarter 2014 Financial Results and Highlights Recent Period Activities
5/8/2014 4:00:00 PM - Business Wire

Alnylam to Webcast Presentation at Bank of America Merrill Lynch 2014 Health Care Conference
5/7/2014 4:00:00 PM - Business Wire

Alnylam Advances Development Candidate for ALN-AAT, a Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) in Development for the Treatment of AAT Deficiency-Associated Liver Disease
5/6/2014 8:00:00 AM - Business Wire

Alnylam to Webcast Conference Call Discussing First Quarter 2014 Financial Results
5/1/2014 4:00:00 PM - Business Wire

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
5/1/2014 11:02:00 AM - Market Wire

Alnylam Presents New Pre-clinical Data on Subcutaneously Delivered RNAi Therapeutics for Cardiovascular Metabolic Disease at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
5/1/2014 11:00:00 AM - Business Wire

Alnylam to Webcast Presentation at Deutsche Bank 39th Annual Health Care Conference
4/30/2014 4:00:00 PM - Business Wire

Tekmira's Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02)
4/28/2014 6:30:00 PM - GlobeNewswire

Alnylam and Collaborators Present New Clinical Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR)
4/28/2014 8:00:00 AM - Business Wire

    • << first
    • < previous
    • 1
    • next >
    • last >>